STOCK TITAN

Kura Oncology’s Brian T. Powl sells 24,450 shares

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
4

Rhea-AI Filing Summary

Kura Oncology, Inc. Chief Commercial Officer Brian T. Powl reported direct sales of 24,450 common shares on November 16 and 17, 2026. The November 16 sale covered 9,196 shares at $7.44 per share to cover taxes associated with vesting of an RSU received on November 13, 2025. On November 17, Powl sold 15,254 shares at a weighted average $7.45 per share under a Rule 10b5-1 trading plan adopted May 22, 2026; executions ranged from $7.24 to $7.74. He also acquired 896 shares through the Employee Stock Purchase Plan on November 17.

Insider Powl Brian T.
Role Chief Commercial Officer
Sold 24,450 shs ($182K)
Type Security Shares Price Value
Sale Common Stock F2, F3, F4 15,254 $7.45 $114K
Sale Common Stock F1 9,196 $7.44 $68K
Holdings After Transaction: Common Stock — 113,265 shares (Direct)
Other Insiders: 4 other insiders reported open-market sales of this stock in the 30 days up to this filing.
Footnotes (4)
  1. F1. Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated November 13, 2025.
  2. F2. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on November 13, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
  3. F3. This transaction was executed in multiple trades at prices ranging from $7.24 to $7.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. F4. 896 shares were acquired on November 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
Shares sold 24,450 shares Across November 16 and 17, 2026
Shares sold 9,196 shares November 16, 2026
Sale price $7.44 per share November 16, 2026
Shares sold 15,254 shares November 17, 2026
Weighted average sale price $7.45 per share November 17, 2026
Execution price range $7.24 to $7.74 per share November 17, 2026 sale
Shares acquired 896 shares Employee Stock Purchase Plan, November 17, 2026
sell-to cover financial
"Sell-to cover for taxes associated with the vesting of an RSU"
restricted stock units financial
"acquired upon vesting of restricted stock units on November 13, 2026"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Rule 10b5-1 trading plan financial
"sales were effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Employee Stock Purchase Plan financial
"acquired on November 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan"
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many KURA shares did Brian T. Powl sell?

Brian T. Powl sold 24,450 common shares across November 16 and 17, 2026: 9,196 shares on November 16 at $7.44 per share and 15,254 shares on November 17 at a weighted average $7.45 per share.

Was Brian T. Powl's November 17 KURA sale made under a 10b5-1 plan?

Yes. The November 17 sale was made under a Rule 10b5-1 trading plan adopted May 22, 2026. The reported execution prices for that sale ranged from $7.24 to $7.74 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Powl Brian T.

(Last)(First)(Middle)
C/O KURA ONCOLOGY, INC.
4930 DIRECTORS PLACE, SUITE 500

(Street)
SAN DIEGO CALIFORNIA 92121

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Commercial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
11/16/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock11/16/2026S(1)9,196D$7.44127,623D
Common Stock11/17/2026S(2)15,254D$7.45(3)113,265(4)D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Sell-to cover for taxes associated with the vesting of an RSU received by the Reporting Person dated November 13, 2025.
2. The shares sold were acquired by the Reporting Person upon vesting of restricted stock units on November 13, 2026. The sales reported herein were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 22, 2026.
3. This transaction was executed in multiple trades at prices ranging from $7.24 to $7.74. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
4. 896 shares were acquired on November 17, 2026 pursuant to the Issuer's Employee Stock Purchase Plan.
Teresa Bair, Attorney-in-fact for Brian Powl11/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Keep reading